Articles from Hangzhou Qihan Biotech Co., Ltd.

Hangzhou Qihan Biotech Co., Ltd. ("Qihan" or "Qihan Biotech" or "the Company"), an industry leader in applying multiplexable genome editing technology to cell therapies and organ transplantation, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for QT-019B. This universal, dual-target CAR-T cell therapy is designed to treat refractory systemic lupus erythematosus (rSLE), and the clearance enables the initiation of a Phase 1/2 clinical trial in the United States, marking a significant milestone in the development of novel cell-based therapies for autoimmune diseases.

Hangzhou Qihan Biotech Co., Ltd. (“Qihan” or “Qihan Biotech” or “the Company”), an industry leader in applying multiplexable genome editing technology to cell therapies and organ transplantation, announced the publication of groundbreaking clinical result in Cell. The study highlights the therapeutic success of Qihan’s off-the-shelf, dual-targeting iPSC-derived CAR-NK cell product, QN-139b, in treating refractory systemic sclerosis (SSc). Conducted in collaboration with Professor Huji Xu’s clinical team at Shanghai Changzheng Hospital, this work marks the first-ever application of iPSC-CAR-NK cells in treating autoimmune disease, representing Qihan’s global leading technology for the cell therapy field.

Hangzhou Qihan Biotech Co., Ltd. ("Qihan" or "Qihan Biotech" or "the Company"), an industry leader in applying multiplexable genome editing technology to cell therapies and organ transplantation, announced new advancements in its universal CAR-T cell therapy research, to be presented at the 28th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT).

Hangzhou Qihan Biotech Co., Ltd. ("Qihan" or "Qihan Biotech" or "the Company"), an industry leader in applying multiplexable genome editing technology to cell therapies and organ transplantation, is proud to announce the appointment of Dr. Carl June as Cell Therapy Chair of its Scientific Advisory Board. In this capacity, Dr. June will oversee strategic scientific initiatives and provide critical guidance on the development of innovative therapies. As a world-renowned scientific leader in the field of immunotherapy, Dr. June’s innovative and groundbreaking work in cancer immunotherapy, particularly CAR-T, has been transformative, offering new hope for patients with previously untreatable cancers.

Hangzhou Qihan Biotech Co., Ltd. ("Qihan" or "Qihan Biotech" or "the Company"), an industry leader in applying multiplexable genome editing technology to cell therapies and organ transplantation, announced its groundbreaking research titled "Testing Multiplexed anti-ASFV CRISPR-Cas9 in Reducing African Swine Fever Virus" in Microbiology Spectrum, an academic journal of the American Society for Microbiology. Qihan Biotech's R&D team led the study in collaboration with Professor Zezhong Zheng of South China Agricultural University, Professor Hongjiang Wei and Professor Hongye Zhao of Yunnan Agricultural University, and Professor George Church and his team at Harvard University.

Hangzhou Qihan Biotech Co., Ltd. ("Qihan" or "Qihan Biotech" or "the Company"), an industry leader in applying multiplexable genome editing technology to cell therapies and organ transplantation, announced today the appointment of Mr. Yingyong Xu as the Chief Medical Officer.

Hangzhou Qihan Biotech Co., Ltd. ("Qihan" or "Qihan Biotech" or "the Company"), an industry leader in applying multiplexable genome editing technology to cell therapies and organ transplantation, today announced the successful completion of a pre-Series B financing exceeding $16 million funded by a new investor, Zhejiang Industrial Fund Co., Ltd., with participation from other existing investors. The combined funds from this financing round and the company's reserves will provide ample capital to support the rapid product iteration and global development of gene-edited stem cell products by Qihan in the next four years.

Hangzhou Qihan Biotech Co., Ltd. ("Qihan" or "Qihan Biotech" or "the Company"), an industry leader in applying multiplexable genome editing technology to cell therapies and organ transplantation, announced today the appointment of Mr. Naxin Yao, as an independent director to its Board of Directors. Mr. Yao is a highly accomplished and respected business leader with extensive experience in corporate management, strategic planning, and global vision.

Hangzhou Qihan Biotech Co., Ltd. ("Qihan" or "Qihan Biotech" or "the Company"), an industry leader in applying multiplexable genome editing technology to cell therapies and organ transplantation, announced today that the National Medical Products Administration (NMPA) approved its clinical trial application for the product QN-019a. It is the first IND approved in China for a gene-edited iPSC-derived cell therapy product.

Hangzhou Qihan Biotech Co., Ltd. ("Qihan" or "Qihan Biotech" or "the Company"), an industry leader in applying multiplexable genome editing technology to cell therapies and organ transplantation, today announced the appointment of Tony W. Ho, M.D., to its Board of Directors as an independent director. Dr. Ho is a highly accomplished leader with extensive experience across all phases of Research & Development, including discovery, early and late-stage clinical development, and regulatory throughout his over 20 years of career, and most recently served as Executive Vice President and Head of Research & Development at CRISPR Therapeutics, where he oversaw the company's global research and development efforts across all therapeutic areas.